Additional file 2: Figure S1. of 3D: diversity, dynamics, differential testing – a proposed pipeline for analysis of next-generation sequencing T cell repertoire data

The diversity of TCR from PBMC at week 0, 2 and 4 for the healthy subjects (left) and the treated prostate cancer subjects (right) in NeoACT study. (A) The clonality of TCR from PBMC at week 0, 2 and 4 for the healthy subjects (left) and the treated prostate cancer subjects (right). (B) The geometric coefficient of variation (GCV) of TCR from PBMC at Week 0, 2 and 4 (PBMC.0, PBMC.2 and PBMC.4) for the healthy subjects (left) and the treated prostate cancer subjects (right). (PDF 1774 kb)